A3 MOA
Research type
Research Study
Full title
Mechanism of Action of Targeted Lung Denervation in Chronic Obstructive Pulmonary Disease A basic science study linked to the AIRFLOW-3 Trial – AIRFLOW-3 sub-study
IRAS ID
269766
Contact name
PL Shah
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Why the research is needed: Chronic obstructive pulmonary disease (COPD) is a disease of the lungs usually caused by smoking which affects more than 300 million people worldwide. Airways become narrow and treatments aim to open up the airways to help breathing. Currently, the main treatment is inhalers, but these can cause side effects, and often don’t fully control symptoms. New treatments are desperately needed.
What we plan to do and why: We plan to study a potential new treatment for COPD called "Targeted Lung Denervation" or "TLD". It is a one-off procedure which aims to open up the airways. We need to learn more about this treatment including the effects it has on the lungs and how it works.
How we plan to do it: AIRFLOW-3 is a trial taking place across the world which will include 400 patients with COPD. We plan to recruit 22 adult patients in the UK from the Royal Brompton Hospital and Chelsea and Westminster Hospital for an add on study where additional tests are performed to assess how TLD works. This add on study will last for 12 months. This will include assessments of how the lungs are working with tests where the function of the lungs are measured by blowing into tubes, and breathing in substances. We will study how TLD affects cells and nerves by collecting samples during bronchoscopies. This will also help us understand how the treatment affects bacteria or viruses, inflammation, cells, and nerves. By understanding more about TLD, we will be able to decide how it may best benefit patients, and how we can most effectively improve health.REC name
East of England - Cambridge East Research Ethics Committee
REC reference
19/EE/0313
Date of REC Opinion
12 Nov 2019
REC opinion
Further Information Favourable Opinion